Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 14/20 | 0.47 |
| ▸ | CA1 | P00915 | 11/20 | 0.47 |
| ▸ | CA4 | P22748 | 7/20 | 0.47 |
| ▸ | CA6 | P23280 | 6/20 | 0.46 |
| ▸ | CA9 | Q16790 | 7/20 | 0.41 |
| ▸ | CA7 | P43166 | 6/20 | 0.41 |
| ▸ | CA12 | O43570 | 6/20 | 0.41 |
| ▸ | CA5A | P35218 | 5/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.41 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CA3 | P07451 | 3/20 | 0.38 |
| ▸ | LDHA | P00338 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2774283 | 0.81 | CA2 (0.42) | CA2CA1CA4CA6CA9 | |
| SCHEMBL3531209 | 0.80 | CA2 (0.61) | CA2CA1CA4CA6CA9 | |
| SCHEMBL3118107 | 0.80 | CCR2 (0.38) | CA2CA1CA4CA6LMNA | |
| SCHEMBL6038911 | 0.79 | CA1 (0.48) | CA2CA1CA4CA6CA9 | |
| SCHEMBL28457862 | 0.77 | CA2 (0.52) | CA2CA1CA4CA6CA9 | |
| SCHEMBL10957617 | 0.77 | LDHA (0.50) | CA2CA1CA4CA6CA9 | |
| SCHEMBL20485996 | 0.76 | CA2 (0.45) | CA2CA1CA4CA6CA9 | |
| SCHEMBL3091342 | 0.76 | CA2 (0.45) | CA2CA1CA4CA6CA9 | |
| SCHEMBL28584478 | 0.74 | HTR2A (0.41) | LMNATDP1L3MBTL1 | |
| SCHEMBL10593744 | 0.73 | CA2 (0.52) | CA2CA1CA4CA6CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7728002-B2 | Use of pyrrolopyridine compounds for activating PPAR receptors and treatment of conditions involving such receptors | LABORATOIRES FOURNIER S.A. (FR) | 2010-06-01 | — | — | US | disclosed |
| US-20090239856-A1 | Use of Pyrrolopyridine Compounds for Activating PPAR Receptors and Treatment of Conditions Involving Such Receptors | LABORATOIRES FOURNIER S.A. (FR) | 2009-09-24 | — | — | US | disclosed |
| US-7557122-B2 | Pyrrolopyridine compounds, method of making them and uses thereof | LABORATOIRES FOURNIER S.A. (FR) | 2009-07-07 | — | — | US | disclosed |
| US-20080200495-A1 | Pyrrolopyridine Compounds, Method of Making Them and Uses Thereof | LABORATOIRES FOURNIER S.A. (FR) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239856-A1 | Use of Pyrrolopyridine Compounds for Activating PPAR Receptors and Treatment of Conditions Involving Such Receptors | PPARD, PPARA, PPARG | CA2 3289/4885CA1 4506/4885CA4 4520/4885 |
| US-20080200495-A1 | Pyrrolopyridine Compounds, Method of Making Them and Uses Thereof | LIPG, PCSK9, PNLIP | CA2 3468/4885CA1 4518/4885CA4 3900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.